Alterations in gut microbial function following liver transplant

Liver Transplantation

Volumn 24, Issue 6, 2018, Pages 752-761

  Bajaj, Jasmohan S ^a   Kakiyama, Genta ^a   Cox, I Jane ^b   Nittono, Hiroshi ^c   Takei, Hajime ^c   White, Melanie ^a   Fagan, Andrew ^a   Gavis, Edith A ^a   Heuman, Douglas M ^a   Gilles, Ho Chong ^a   Hylemon, Phillip ^a   Taylor Robinson, Simon D ^d   Legido Quigley, Cristina ^e   Kim, Min ^e   Xu, Jin ^e   Williams, Roger ^b   Sikaroodi, Masoumeh ^f   Pandak, William M ^a   Gillevet, Patrick M ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INSTITUTE OF HEPATOLOGY   (United Kingdom)

^c Junshin Clinic Bile Acid Institute   (Japan)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; BILE ACID; CYCLOSPORINE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; TRIMETHYLAMINE OXIDE;

ADULT; AMMONIA BLOOD LEVEL; ARTICLE; BILE ACID METABOLISM; CELL MEMBRANE; COGNITION; CONTROLLED STUDY; DYSBIOSIS; ENDOTOXEMIA; FEMALE; HEPATITIS C; HUMAN; INTESTINE FLORA; LIPID BLOOD LEVEL; LIPIDOMICS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MICROBIAL DIVERSITY; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUROTOXICITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; BLOOD; COMPARATIVE STUDY; END STAGE LIVER DISEASE; FECES; LIPID METABOLISM; LIVER; LIVER FUNCTION TEST; METABOLISM; METABOLOME; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BILE ACIDS AND SALTS; COGNITION; DYSBIOSIS; END STAGE LIVER DISEASE; ENDOTOXEMIA; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; METABOLOME; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85048346028     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.25046     Document Type: Article

References (42)

1. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014;59:1144-1165.
2. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014;60:940-947.
3. Chen Y, Guo J, Qian G, Fang D, Shi D, Guo L, Li L. Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality. J Gastroenterol Hepatol 2015;30:1429-1437.
4. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63.
5. Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-955.
6. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:205-208.
7. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-735.
8. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-254.
9. Bajaj JS, Fagan A, Sikaroodi M, White MB, Sterling RK, Gilles H, et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. Liver Transpl 2017;23:907-914.
10. Doycheva I, Leise MD, Watt KD. The intestinal microbiome and the liver transplant recipient: what we know and what we need to know. Transplantation 2016;100:61-68.
11. Zhang Y, Chen J, Wu J, Chalson H, Merigan L, Mitchell A. Probiotic use in preventing postoperative infection in liver transplant patients. Hepatobiliary Surg Nutr 2013;2:142-147.
12. Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, et al. Diagnosis of minimal hepatic encephalopathy using stroop encephalapp: a multicenter US-based, norm-based study. Am J Gastroenterol 2016;111:78-86.
13. Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 2009;15:4225-4233.
14. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60.
15. Quantitative Insights Into Microbial Ecology. http://qiime.org/tutorials/tutorial.html. Accessed March 22, 2018.
16. Muto A, Takei H, Unno A, Murai T, Kurosawa T, Ogawa S, et al. Detection of Delta4-3-oxo-steroid 5beta-reductase deficiency by LC-ESI-MS/MS measurement of urinary bile acids. J Chromatogr B Analyt Technol Biomed Life Sci 2012;900:24-31.
17. Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014;307:G951-G957.
18. Xu J, Casas-Ferreira AM, Ma Y, Sen A, Kim M, Proitsi P, et al. Lipidomics comparing DCD and DBD liver allografts uncovers lysophospholipids elevated in recipients undergoing early allograft dysfunction. Sci Rep 2015;5:17737.
19. Wu ZW, Ling ZX, Lu HF, Zuo J, Sheng JF, Zheng SS, Li LJ. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int 2012;11:40-50.
20. Campagna F, Biancardi A, Cillo U, Gatta A, Amodio P. Neurocognitive-neurological complications of liver transplantation: a review. Metab Brain Dis 2010;25:115-124.
21. Campagna F, Montagnese S, Schiff S, Biancardi A, Mapelli D, Angeli P, et al. Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl 2014;20:977-986.
22. Ling Q, Xu X, Wang B, Li L, Zheng S. The origin of new-onset diabetes after liver transplantation: liver, islets, or gut? Transplantation 2016;100:808-813.
23. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids, and gut microbiota: unraveling a complex relationship. Gut Microbes 2013;4:382-387.
24. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26-42.
25. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007;46:816-826.
26. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 2016;24:41-50.
27. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-259.
28. Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature 2015;525:E1-E2.
29. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19:576-585.
30. Bajaj JS, Gillevet PM, Patel NR, Ahluwalia V, Ridlon JM, Kettenmann B, et al. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy. Metab Brain Dis 2012;27:205-215.
31. Jiménez B, Montoliu C, MacIntyre DA, Serra MA, Wassel A, Jover M, et al. Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. J Proteome Res 2010;9:5180-5187.
32. Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio 2015;6:e02481.
33. Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome 2017;5:54.
34. Ierardi E, Sorrentino C, Principi M, Giorgio F, Losurdo G, Di Leo A. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr 2015;4:289-292.
35. Connor SL, Connor WE. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am J Clin Nutr 1997;66(suppl):1020S-1031S.
36. Ota N, Soga S, Hase T, Tokimitsu I, Murase T. Dietary diacylglycerol induces the regression of atherosclerosis in rabbits. J Nutr 2007;137:1194-1199.
37. Kummerow FA. Interaction between sphingomyelin and oxysterols contributes to atherosclerosis and sudden death. Am J Cardiovasc Dis 2013;3:17-26.
38. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167.
39. Barter P, Rye KA. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends Pharmacol Sci 2011;32:694-699.
40. Rudel LL, Shelness GS. Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med 2000;6:1313-1314.
41. Qu F, Zheng SJ, Wu CS, Jia ZX, Zhang JL, Duan ZP. Lipidomic profiling of plasma in patients with chronic hepatitis C infection. Anal Bioanal Chem 2014;406:555-564.
42. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484.